These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20092221)

  • 1. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic and functional differentiation of tapentadol and tramadol.
    Raffa RB; Buschmann H; Christoph T; Eichenbaum G; Englberger W; Flores CM; Hertrampf T; Kögel B; Schiene K; Straßburger W; Terlinden R; Tzschentke TM
    Expert Opin Pharmacother; 2012 Jul; 13(10):1437-49. PubMed ID: 22698264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol.
    Nossaman VE; Ramadhyani U; Kadowitz PJ; Nossaman BD
    Anesthesiol Clin; 2010 Dec; 28(4):647-66. PubMed ID: 21074743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs.
    Kögel B; Terlinden R; Schneider J
    Vet Anaesth Analg; 2014 May; 41(3):297-304. PubMed ID: 24576316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
    Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
    J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
    Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R
    Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.
    Stoops WW; Glaser PE; Rush CR
    Psychopharmacology (Berl); 2013 Jul; 228(2):255-62. PubMed ID: 23430163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.
    Roulet L; Rollason V; Desmeules J; Piguet V
    Drugs; 2021 Jul; 81(11):1257-1272. PubMed ID: 34196947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacology and toxicology of tramadol and tapentadol.
    Faria J; Barbosa J; Moreira R; Queirós O; Carvalho F; Dinis-Oliveira RJ
    Eur J Pain; 2018 May; 22(5):827-844. PubMed ID: 29369473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy.
    Desai B; Freeman E; Huang E; Hung A; Knapp E; Breunig IM; McPherson ML; Shaya FT
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):203-9. PubMed ID: 24524594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review.
    Vadivelu N; Chang D; Helander EM; Bordelon GJ; Kai A; Kaye AD; Hsu D; Bang D; Julka I
    Anesthesiol Clin; 2017 Jun; 35(2):e1-e20. PubMed ID: 28526155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tapentadol--the evidence so far.
    Ramaswamy S; Chang S; Mehta V
    Anaesthesia; 2015 May; 70(5):518-22. PubMed ID: 25866038
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.